JW0104+C2402
Phase 3Small molecule
JW0104+C2402 is one of 34 small molecule programs targeting Hypertension. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
161 competitors in Hypertension
#DrugCompanyPhaseTrials
1Foundayo
Eli LillyPhase 3
Nitrostat
VViatris Specialty LLC
Phase 3
Baxfendy
AstraZenecaPhase 3
Alka-Seltzer
AAbbott
Phase 3
JW0104+C2402
JJW Pharmaceutical
Phase 3
Avastin
RochePreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Nipride
EExela Pharma Sciences, LLC.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JW0104+C2402. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- JJW Pharmaceutical